Rossari Biotech Ltd.
NSE: ROSSARI · Chemicals
Sector
Chemicals
Size band
Small cap
Market cap
2,461cr
P/E
20.4
ROE
11.3%
Dividend yield
0.1%
No price is shown on this page, live or delayed. It records what management said on the earnings call, and the company’s filings.
Measured against
Peer set
Speciality Chemicals · largest 12 of 32 measured at Q1 FY27 · financials via Screener| Company | Operating margin | Revenue growth |
|---|---|---|
| Gujarat Fluorochemicals Ltd. | 27.0% | 24.0% |
| Navin Fluorine International Ltd. | 34.0% | 44.1% |
| Atul Ltd. | 21.0% | 25.0% |
| Aarti Industries Ltd. | 16.0% | 42.5% |
| Aether Industries Ltd. | 31.0% | 27.2% |
| Anupam Rasayan India Ltd. | 25.0% | 34.8% |
| Vinati Organics Ltd. | 24.0% | 28.4% |
| Privi Speciality Chemicals Ltd. | 23.0% | 19.1% |
| Jubilant Ingrevia Ltd. | 15.0% | 25.2% |
| Clean Science And Technology Ltd. | 36.0% | 10.3% |
| Alkyl Amines Chemicals Ltd. | 25.0% | 30.0% |
| Rossari Biotech Ltd. | 12.0% | 28.1% |
No guidance on record.
This section quotes what management told the market on the quarterly earnings call. We have not transcribed one for Rossari Biotech Ltd..
No broadcast calls recorded.
We log calls made about a company on business television — Zee Business, CNBC Awaaz and NDTV Profit — as they are stated on air. Nothing is on record for Rossari Biotech Ltd..
Shareholding
change across 4 filings| Category | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Change |
|---|---|---|---|---|---|
| Promoters | 68.1 | 68.1 | 68.2 | 68.2 | −0.1 |
| Foreign institutions | 1.8 | 2.0 | 2.2 | 2.3 | −0.5 |
| Domestic institutions | 14.2 | 14.6 | 18.2 | 18.3 | −4.1 |
| Retail & others | 15.8 | 15.2 | 11.5 | 11.3 | +4.5 |
As filed with the exchange for the periods ending Dec 25 to Sep 26.
Filings
latest 25 of 222- Press Release19 Oct 2026
- Investor Presentation19 Oct 2026
- Analysts/Institutional Investor Meet/Con. Call Updates14 Oct 2026
- Certificate under SEBI (Depositories and Participants) Regulations, 20186 Oct 2026
- Trading Window25 Sept 2026
- Analysts/Institutional Investor Meet/Con. Call Updates16 Sept 2026
- Intimation of Analyst/ Institutional Investor Meet/ Con. Call/Updates.16 Sept 2026
- Intimation of Analyst/Institutional Investors Meet/Con. Call/Updates.10 Sept 2026
- Analysts/Institutional Investor Meet/Con. Call Updates10 Sept 2026
- Updates6 Aug 2026
- Analysts/Institutional Investor Meet/Con. Call Updates3 Aug 2026
- Analysts/Institutional Investor Meet/Con. Call Updates24 Jul 2026
- Scrutinizer''s Report for the 17th Annual General Meeting of the Members of the Company.20 Jul 2026
- Outcome of 17th Annual General Meeting of the Members of the Company along with Proceedings, Voting Results and Scrutinizers Report.20 Jul 2026
- Shareholders meeting20 Jul 2026
- Analysts/Institutional Investor Meet/Con. Call Updates20 Jul 2026
- ESOP/ESOS/ESPS20 Jul 2026
- Analysts/Institutional Investor Meet/Con. Call Updates14 Jul 2026
- Rossari Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 18/07/2026 ,inter alia, to consider and approve Unaudited Financial Results ....10 Jul 2026
- Certificate under SEBI (Depositories and Participants) Regulations, 20187 Jul 2026
- Commencement of commercial production/operations26 Jun 2026
- Trading Window25 Jun 2026
- Copy of Newspaper Publication19 Jun 2026
- Updates18 Jun 2026
- Record Date18 Jun 2026
The 25 most recent of 222 filings we hold for ROSSARI, back to January 2024. Every filing, by day.
Disclaimer
Guidance is quoted from management commentary on quarterly earnings calls; the words are the company's own and the targets are theirs, not ours. Peer comparisons use quarterly financials sourced from Screener, with every company measured at the same fiscal quarter; the peer set is companies sharing the same industry classification, and comparisons are descriptive, not a ranking or a view. Filings are reproduced as companies filed them to the NSE and BSE; Bharatstox does not verify, endorse or comment on their contents. This page is for informational and educational purposes only and does not constitute investment advice, research, or a recommendation to buy or sell any security. Investing in securities markets is subject to market risks. Read all related documents carefully before investing.